Back to News
Market Impact: 0.2
Lilly, Hims & Hers Partner To Expand Access To Weight-Loss Medicines; Stock Up
Source: Nasdaq
Healthcare & BiotechProduct Launches
Eli Lilly and Hims & Hers Health agreed to expand access to Lilly’s FDA-approved obesity treatments through the Hims & Hers telehealth platform. The announcement provides no details on expected patient reach, financial terms, or timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
HIMS0.50
LLY0.50
More News
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- Our top 10 things to watch in the stock market Friday
- Why is Hims & Hers Health stock rallying today?
- Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Tesla to wind down Cybertruck production at Texas factory next year to make room for Cybercab